Pfenex Awards a Contract to Paragon Bioservices
News Nov 07, 2013
Pfenex Inc. has announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine.
Paragon Bioservices will implement the cGMP-ready Pfēnex Expression Technology™-based production process that has been developed at Pfenex, through its vaccines division.
Funding will be provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).
“We are pleased to award this contract to Paragon Bioservices,” stated Bertrand C. Liang, Chief Executive Officer, “This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase 1 clinical trial.”
Marco A. Chacón, Ph.D., CEO of Paragon stated, “My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons.”
Radical New Approach to Vaccine Development Could Help Reduce Illness From FluNews
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.READ MORE
Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic DiscoveryNews
A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.READ MORE